Soluble CD27 differentially predicts resistance to anti-PD1 alone but not with anti-CTLA-4 in melanoma
Abstract Metastatic melanoma can be treated with anti-PD-1 monotherapy or in combination with anti-CTLA-4 or anti-Lag3. However, combination therapy is associated with a high risk of toxicity. Recently, we reported that high plasma soluble CD27 (sCD27) levels reflect the intratumoral interaction of...
Збережено в:
| Автори: | , , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Springer Nature
2025-03-01
|
| Серія: | EMBO Molecular Medicine |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1038/s44321-025-00203-9 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
